StockNews.AI

Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026

StockNews.AI • 3 hours

ABBVREGNAMGN
High Materiality8/10

Information

– Announced new data demonstrating a unique mechanism of action supporting the best-in-class potenti...

Original source

AI Summary

Connect Biopharma highlights rademikibart's best-in-class potential data. Ongoing Phase 1b study aims to improve airway function rapidly. Phase 2 studies for asthma and COPD planned for mid-2026 results. Strong financial position supports operations through 2027 clinical milestones.

Sentiment Rationale

The positive data on rademikibart enhances its therapeutic potential, similar to successful past biopharma advancements that saw stock rises upon favorable study outcomes.

Trading Thesis

Upcoming data reads from Phase 1b study in Q1 2026 and Phase 2 studies in mid-2026 may lead to short-term stock price reactions.

Market-Moving

  • Connect Biopharma highlights rademikibart's best-in-class potential data.
  • Ongoing Phase 1b study aims to improve airway function rapidly.
  • Phase 2 studies for asthma and COPD planned for mid-2026 results.

Key Facts

  • Connect Biopharma highlights rademikibart's best-in-class potential data.
  • Ongoing Phase 1b study aims to improve airway function rapidly.
  • Phase 2 studies for asthma and COPD planned for mid-2026 results.
  • Strong financial position supports operations through 2027 clinical milestones.

Companies Mentioned

  • ABBV (ABBV)
  • REGN (REGN)
  • AMGN (AMGN)

Research Analysis

New data on rademikibart directly influences investor sentiment and may affect stock movement due to clinical milestone expectations.

Connect Biopharma Announces Promising Data for Rademikibart and Strategic Priorities for 2026

San Diego, CA, January 12, 2026 – Connect Biopharma Holdings Limited (Nasdaq: CNTB), a clinical-stage biopharmaceutical company dedicated to advancing treatments for inflammatory diseases, has unveiled new data showcasing a distinct mechanism of action for its lead product, rademikibart. The company discussed its strategic priorities and ongoing clinical trials set to play a pivotal role in its development pipeline for 2026.

Breakthrough Mechanism of Action Data

The latest findings highlight rademikibart's potential as a best-in-class therapeutic option. Barry Quart, Pharm.D., CEO of Connect Biopharma, stated, “The new mechanism of action data support rademikibart's ability to swiftly counteract the detrimental effects of interleukin-4 (IL-4) and interleukin-13 (IL-13) on airway function. This results in a quicker onset of therapeutic action along with superior improvement in forced expiratory volume in one second (FEV1) and minimized eosinophil-related side effects.”

Current Clinical Trials and Expectations

Connect Biopharma is actively recruiting participants for:

  • Phase 1b Study: Focused on the intravenously administered rademikibart, aimed at confirming its rapid ability to enhance airway function with topline results projected in Q1 2026.
  • Phase 2 Seabreeze STAT Studies: Evaluating rademikibart’s effectiveness for managing acute exacerbations in asthma and chronic obstructive pulmonary disease (COPD), with topline data expected by mid-2026.

Financial Position and Future Outlook

As of September 30, 2025, Connect Biopharma holds $54.8 million in cash, cash equivalents, and short-term investments. This strong balance sheet is anticipated to support operations into 2027, enabling the company to navigate through key clinical catalysts.

About Rademikibart

Rademikibart functions as a fully human monoclonal antibody targeting the interleukin-4 receptor alpha (IL-4Rα), a vital component in managing Th2-related inflammatory diseases, including asthma and atopic dermatitis. The drug’s unique pharmacologic profile aims to block the action pathways of IL-4 and IL-13 effectively.

About Connect Biopharma

With its headquarters in San Diego, California, Connect Biopharma is committed to innovating care in treating asthma and COPD with rademikibart. The company is currently conducting extensive global clinical evaluations of rademikibart and has partnered with Simcere Pharmaceutical Co., Ltd., for exclusive rights in Greater China, potentially yielding milestone payments up to $110 million upon achieving specific development milestones.

Forward-Looking Statements

This announcement contains forward-looking statements regarding Connect Biopharma's future plans, including anticipated clinical outcomes and financial stability. These statements are based on the management's current expectations and carry inherent risks and uncertainties.

For more detailed information, please visit www.connectbiopharma.com.

Related News